Article
Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer.
Cancer research - 15 Jan 2007
Climent Joan, Dimitrow Peter, Fridlyand Jane, Palacios Jose, Siebert Reiner, Albertson Donna G, Gray Joe W, Pinkel Daniel, Lluch Ana, Martinez-Climent Jose A
Abstract excerpt
Despite the recent consensus on the eligibility of adjuvant systemic therapy in patients with lymph node-negative breast cancer (NNBC) based on clinicopathologic criteria, specific biological markers are needed to predict sensitivity to the different available therapeutic options. We examined the feasibility of developing a genomic predictor of chemotherapy response and recurrence risk in 185 patients with NNBC...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.